The MEK 1/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into PAMAM-coated PLGA-PEG nanoparticles
Kanawat Wiwatchaitawee, Aml I. Mekkawy, Juliana C. Quarterman, Youssef W. Naguib, Kareem Ebeid, Sean M. Geary, Aliasger K. Salem
Topics & Concepts
PaclitaxelIn vivoBiodistributionChemistryPolyethylene glycolPharmacologyPharmacokineticsIn vitroEndometrial cancerPEG ratioCytotoxicityDistribution (mathematics)Cancer researchCancerMedicineBiochemistryInternal medicineBiologyEconomicsMathematicsFinanceBiotechnologyMathematical analysisNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsCellular Mechanics and Interactions